News

Article

AJMC® in the Press, October 11, 2024

Author(s):

AJMC Staff

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article from Becker’s GI & Endoscopy referenced an article published on AJMC.com, the website of The American Journal of Managed Care® (AJMC®). The article, “Updated Colonoscopy Guidelines Have Implications on Doctors, Patients Alike,” discussed the effect that the new colonoscopy guidelines published by the American College of Gastroenterology and American Society for Gastrointestinal Endoscopy would have on doctors and patients as they slowly become implemented.

An article from Pharmacy Times® referenced an article published by AJMC’s sister site, The Center for Biosimilars®. The article, “Mark Cuban’s Online Pharmacy Partners With Coherus Biosciences for Humira Biosimilar,” reported on Coherus Biosciences teamed up with Mark Cuban’s online pharmacy to make a biosimilar that referenced adalimumab, which would be offered at an affordable price for patients.

Related Videos
Io Hui, PhD, researcher at The University of Edinburgh
Adam Colborn, JD, of AMCP
Corey McEwen, PharmD, MS
Daniel Howell, MBBS
Related Content
Breast screening | Image Credit: Valerii Apetroaiei - stock.adobe.com
October 11th 2024

5 Things to Know Before a Breast Screening

Cameron Santoro
Here are 5 key points for pre–breast screening preparation that cover the areas of risk assessment, lifestyle adjustments, understanding screening details, managing anxiety, and open provider communication.
managed care cast logo
October 3rd 2024

Dr Rick Chapman Discusses Key Insights From the Center’s Rare Disease Project

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.
Aaron Gerds, MS, MS | Image credit: Cleveland Clinic
October 11th 2024

NCCN Guidelines for MPN Reflect New Drugs, Focus on Clinical Trials

Interview by Mary Caffrey
An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024

Sustaining Compassionate Trauma Care Across Communities

Maggie L. Shaw
September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Calculating cost | Image credit: joyfotoliakid - stock.adobe.com
October 10th 2024

Cost Effectiveness Varies in TAS-102 Plus Bevacizumab Third Line Treatment

Julia Bonavitacola
Patients with refractory metastatic colorectal cancer could use trifluridine/tipiracil (TAS-102) plus bevacizumab as a cost effective third line treatment in China but the same was not found in the United States and United Kingdom.
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
October 10th 2024

Advancing Breast Cancer Care With HER2-Targeted Therapies

Maggie L. Shaw
In this interview from our Institute for Value-Based Medicine® event in Boston, we speak with Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, on the clinical significance and cost implications of HER2 in the breast cancer space.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo